Regeneron Pharmaceuticals (REGN)
(Delayed Data from NSDQ)
$962.49 USD
-3.81 (-0.39%)
Updated Mar 28, 2024 04:00 PM ET
After-Market: $959.25 -3.24 (-0.34%) 7:44 PM ET
3-Hold of 5 3
C Value D Growth F Momentum F VGM
Price, Consensus and EPS Surprise
REGN 962.49 -3.81(-0.39%)
Will REGN be a Portfolio Killer in March?
Zacks Investment Research is releasing its prediction for REGN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for REGN
Biotech Stock Roundup: PRAX, VKTX Up on Study Results & MRNA, REGN Give Updates
Should You Invest in the iShares Biotechnology ETF (IBB)?
REGN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Regeneron's (REGN) Lymphoma Candidate Rejected by the FDA
Top Research Reports for JPMorgan Chase, Merck & SAP
Intellia (NTLA) Begins Dosing in Phase III ATTR Amyloidosis Study
Other News for REGN
Behind the Scenes of Regeneron Pharmaceuticals's Latest Options Trends
Xeris gains as Oppenheimer highlights drug technology
Regeneron Pharmaceuticals Inc. stock outperforms competitors despite losses on the day
SillaJen Submits CSR to the US FDA for REN026 Study in Patients with RCC
Decoding 12 Analyst Evaluations For Regeneron Pharmaceuticals